Regulus Therapeutics Overview
Latest ROE for Regulus Therapeutics: -68.85% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-68.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, RGLS shows a ROE of -68.85%. That is below the Healthcare sector average of 20.86%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 20.86%. Regulus Therapeutics is at -68.85%, which is lower that average. That is roughly 430.1% below the sector mean. Use the comparison chart on this page to see how RGLS stacks up against individual peers as well.
Check the historical chart to see whether RGLS's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Regulus Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Regulus Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -68.85%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 20.86%, while RGLS is at -68.85%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
